menu
    • menu
    [{"orgOrder":0,"company":"Premier","sponsor":"Baudax Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Meloxicam","moa":"COX-2","graph1":"Neurology","graph2":"Approved FDF","graph3":"Premier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Premier \/ Baudax Bio","highestDevelopmentStatusID":"15","companyTruncated":"Premier \/ Baudax Bio"},{"orgOrder":0,"company":"Premier","sponsor":"Trevena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Premier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Premier \/ Trevena","highestDevelopmentStatusID":"15","companyTruncated":"Premier \/ Trevena"},{"orgOrder":0,"company":"Premier","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Partnership","leadProduct":"Heparin Sodium","moa":"Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Premier","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Premier \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"Premier \/ Fresenius Kabi AG"}]

    Find Clinical Drug Pipeline Developments & Deals by Premier

    Menu

    Premier

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Premier

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Premier

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oliceridine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Trevena

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Trevena Awarded OLINVYK Agreement with Premier, Inc.

                            Details : Under the agreement, Trevena awarded Premier to take advantage of special pricing for Olinvyk. Olinvyk contains oliceridine, an opioid, which is a Schedule II controlled substance with a high potential for abuse similar to other opioids.

                            Product Name : Olinvyk

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 12, 2023

                            Lead Product(s) : Oliceridine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Trevena

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Premier

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Premier

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Heparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Fresenius Kabi AG

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ProvideGx® Partners with Fresenius Kabi to Help Stabilize Supply of Heparin

                            Details : Premier with Fresenius Kabi aims at supplying pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpati...

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            November 18, 2020

                            Lead Product(s) : Heparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Fresenius Kabi AG

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Premier

                            U.S.A arrow
                            World Vaccine Conference
                            Not Confirmed

                            Premier

                            U.S.A arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meloxicam

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Baudax Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Baudax Bio Awarded Group Purchasing Agreement with Premier Inc. for ANJESO®

                            Details : The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other no...

                            Product Name : Anjeso

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 25, 2020

                            Lead Product(s) : Meloxicam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Baudax Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth